BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 12595050)

  • 1. A636P is associated with early-onset colon cancer in Ashkenazi Jews.
    Guillem JG; Rapaport BS; Kirchhoff T; Kolachana P; Nafa K; Glogowski E; Finch R; Huang H; Foulkes WD; Markowitz A; Ellis NA; Offit K
    J Am Coll Surg; 2003 Feb; 196(2):222-5. PubMed ID: 12595050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population.
    Foulkes WD; Thiffault I; Gruber SB; Horwitz M; Hamel N; Lee C; Shia J; Markowitz A; Figer A; Friedman E; Farber D; Greenwood CM; Bonner JD; Nafa K; Walsh T; Marcus V; Tomsho L; Gebert J; Macrae FA; Gaff CL; Paillerets BB; Gregersen PK; Weitzel JN; Gordon PH; MacNamara E; King MC; Hampel H; De La Chapelle A; Boyd J; Offit K; Rennert G; Chong G; Ellis NA
    Am J Hum Genet; 2002 Dec; 71(6):1395-412. PubMed ID: 12454801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gynecologic malignancies in Ashkenazi families with the MSH2 A636P founder mutation.
    Lavie O; Gruber SB; Lejbkowicz F; Dishon S; Rennert G
    Am J Obstet Gynecol; 2008 Aug; 199(2):148.e1-3. PubMed ID: 18674656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and genetic findings in an Ashkenazi Jewish population with colorectal neoplasms.
    Zauber NP; Sabbath-Solitare M; Marotta S; Zauber AG; Foulkes W; Chan M; Turner F; Bishop DT
    Cancer; 2005 Aug; 104(4):719-29. PubMed ID: 15959913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HNPCC associated MSH2*1906G-->C founder mutation probably originated between 1440 CE and 1715 CE in the Ashkenazi Jewish population.
    Sun S; Greenwood CM; Thiffault I; Hamel N; Chong G; Foulkes WD
    J Med Genet; 2005 Oct; 42(10):766-8. PubMed ID: 16199548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic analyses in consecutive israeli jewish colorectal cancer patients.
    Fidder HH; Figer A; Geva R; Flex D; Schayek H; Avidan B; Meir SB; Friedman E
    Am J Gastroenterol; 2005 Jun; 100(6):1376-80. PubMed ID: 15929773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-amplicon MSH2 A636P mutation testing in Ashkenazi Jewish patients with colorectal cancer: role in presurgical management.
    Guillem JG; Glogowski E; Moore HG; Nafa K; Markowitz AJ; Shia J; Offit K; Ellis NA
    Ann Surg; 2007 Apr; 245(4):560-5. PubMed ID: 17414604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer.
    Laitman Y; Herskovitz L; Golan T; Kaufman B; Paluch SS; Friedman E
    Fam Cancer; 2012 Jun; 11(2):243-7. PubMed ID: 22219001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Report on de-novo mutation in the MSH2 gene as a rare event in hereditary nonpolyposis colorectal cancer.
    Morak M; Laner A; Scholz M; Madorf T; Holinski-Feder E
    Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1101-5. PubMed ID: 19047842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A636P testing in Ashkenazi Jews.
    Guillem JG; Moore HG; Palmer C; Glogowski E; Finch R; Nafa K; Markowitz AJ; Offit K; Ellis NA
    Fam Cancer; 2004; 3(3-4):223-7. PubMed ID: 15516845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The I1307K APC mutation does not predispose to colorectal cancer in Jewish Ashkenazi breast and breast-ovarian cancer kindreds.
    Petrukhin L; Dangel J; Vanderveer L; Costalas J; Bellacosa A; Grana G; Daly M; Godwin AK
    Cancer Res; 1997 Dec; 57(24):5480-4. PubMed ID: 9407954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline novel MSH2 deletions and a founder MSH2 deletion associated with anticipation effects in HNPCC.
    Stella A; Surdo NC; Lastella P; Barana D; Oliani C; Tibiletti MG; Viel A; Natale C; Piepoli A; Marra G; Guanti G
    Clin Genet; 2007 Feb; 71(2):130-9. PubMed ID: 17250661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recognising hereditary non-polyposis colorectal cancer without a clear family history].
    de Bruin JH; Nagengast FM; Ligtenberg MJ; van Krieken JH; Niermeijer MF; Hoogerbrugge N
    Ned Tijdschr Geneeskd; 2004 Oct; 148(42):2053-7. PubMed ID: 15532325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel.
    Figer A; Irmin L; Geva R; Flex D; Sulkes J; Sulkes A; Friedman E
    Br J Cancer; 2001 Feb; 84(4):478-81. PubMed ID: 11207041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel missense MSH2 gene mutation in a patient of a Korean family with hereditary nonpolyposis colorectal cancer.
    Park SJ; Lee KA; Park TS; Kim NK; Song J; Kim BY; Choi JR
    Cancer Genet Cytogenet; 2008 Apr; 182(2):136-9. PubMed ID: 18406877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC.
    Laken SJ; Petersen GM; Gruber SB; Oddoux C; Ostrer H; Giardiello FM; Hamilton SR; Hampel H; Markowitz A; Klimstra D; Jhanwar S; Winawer S; Offit K; Luce MC; Kinzler KW; Vogelstein B
    Nat Genet; 1997 Sep; 17(1):79-83. PubMed ID: 9288102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Msh2 deficiency increases the mutation frequency in all parts of the mouse colon.
    Zhang S; Lloyd R; Bowden G; Glickman BW; de Boer JG
    Environ Mol Mutagen; 2002; 40(4):243-50. PubMed ID: 12489114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple epithelial and nonepithelial tumors in hereditary nonpolyposis colorectal cancer: characterization of germline and somatic mutations of the MSH2 gene and heterogeneity of replication error phenotypes.
    Huang RL; Chao CF; Ding DC; Yu CP; Chang CC; Lai HC; Yu MH; Liu HS; Chu TY
    Cancer Genet Cytogenet; 2004 Sep; 153(2):108-14. PubMed ID: 15350299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New founding mutation in MSH2 associated with hereditary nonpolyposis colorectal cancer syndrome on the Island of Tenerife.
    Medina-Arana V; Barrios Y; Fernández-Peralta A; Herrera M; Chinea N; Lorenzo N; Jiménez A; Martín-López JV; González-Hermoso F; Salido E; González-Aguilera JJ
    Cancer Lett; 2006 Dec; 244(2):268-73. PubMed ID: 16500024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study.
    Drucker L; Stackievitz R; Shpitz B; Yarkoni S
    Anticancer Res; 2000; 20(1B):559-61. PubMed ID: 10769725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.